Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1020569-65-6

Post Buying Request

1020569-65-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1020569-65-6 Usage

Description

Ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate, commonly known as Ioxapiprol, is a synthetic chemical compound that belongs to the class of isoxazoles. It is characterized by its ability to act as a potent insecticide and acaricide, specifically designed to control a broad spectrum of pests such as mites, aphids, thrips, and whiteflies. Ioxapiprol operates by targeting and disrupting the nervous system of these pests, resulting in paralysis and death. ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate is typically applied as a foliar spray and is recognized for its effectiveness in managing pest infestations while minimizing harm to non-target organisms and the environment.

Uses

Used in Agricultural Applications:
Ioxapiprol is used as an insecticide and acaricide for controlling pests in various crops such as fruits, vegetables, and ornamental plants. It is applied as a foliar spray to target pests like mites, aphids, thrips, and whiteflies, disrupting their nervous systems and leading to their death. This helps in protecting the crops from damage and ensuring a healthy yield.
Used in Environmental Protection:
Ioxapiprol is used as an environmentally friendly pest control agent, as it is designed to minimize harm to non-target organisms and the environment. Its targeted action on pests and adherence to safety guidelines and regulations contribute to its role in environmental protection.

Check Digit Verification of cas no

The CAS Registry Mumber 1020569-65-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,0,5,6 and 9 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1020569-65:
(9*1)+(8*0)+(7*2)+(6*0)+(5*5)+(4*6)+(3*9)+(2*6)+(1*5)=116
116 % 10 = 6
So 1020569-65-6 is a valid CAS Registry Number.

1020569-65-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolecarboxylate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1020569-65-6 SDS

1020569-65-6Relevant articles and documents

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio

Gu, Yipei,Leng, Ying,Ning, Mengmeng,Shen, Jianhua,Tang, Xuehang,Yan, Hongyi,Ye, Yangliang

, (2021/07/16)

The farnesoid X receptor (FXR) is a promising therapeutic target for nonalcoholic steatohepatitis (NASH) and other bile acid related diseases because it plays a critical role in fibrosis, inflammation and bile acid homeostasis. Obeticholic acid (OCA), a FXR agonist which was synthesized from chenodeoxycholic acid, showed desirable curative effects in clinical trials. However, the pruritus which was the main side effect of OCA limited its further applications in NASH. Although pruritus was also observed in the clinical trials of non-steroidal FXR agonists, the proportion of patients with pruritus was much smaller than that of OCA. Thus, we decided to develop non-steroidal FXR agonists and discovered a series of novel FXR agonists which were synthesized from GW4064 by replacing the stilbene group with ketoxime ether. Encouragingly, in the following biological tests, our target compounds 13j and 13z not only showed potent FXR agonistic activities in vitro, but also effectively promoted the expression of target genes in vivo. More importantly, in the pharmacokinetic experiments, compounds 13j and 13z displayed high liver/blood ratio characteristics which were helpful to reduce the potential side effects which were caused by prolonged systemic activation of FXR. In summary, our compounds were good choices for the development of non-steroidal FXR agonists and were deserved further investigation.

HETEROCYCLIC FXR MODULATORS

-

, (2018/05/16)

The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF

-

, (2018/11/10)

The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor(FXR, NR1H4).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1020569-65-6